On 26 February the National Research Center for Transfusion and Medical Biotechnology started measuring levels of virus neutralizing antibodies in convalescent plasma.
The center was the first in the CIS to embark on such a study, BelTA learned from the center.
“The National Research Center for Transfusion and Medical Biotechnology was the first in the CIS to start measuring IgG antibody levels against S viral protein,” the center informed. The study involves convalescent plasma donors.
This will allow establishing the gold standard for determining convalescent plasma with high anti–SARS-CoV-2 IgG antibody levels. It will also help accurately assess viral neutralization responses to SARS-CoV-2 in those who have been infected or vaccinated.
BelTA
